We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 1,198

Obamacare in the cross hairs but procedural hurdles loom
  • Foley & Lardner LLP
  • USA
  • January 19 2017

President-elect Trump and congressional Republicans have promised to “repeal and replace” the Affordable Care Act (ACA), but there is deep division


What Is The Trump Pharmaceutical Policy?
  • Foley & Lardner LLP
  • USA
  • January 17 2017

Pharmaceutical stocks took a hit after President-elect Trump criticized the industry during his January 11, 2017 press conference. But he also


Massachusetts Has Legalized Marijuana Should Your Workplace Policies Go Up in Smoke?
  • Foley & Lardner LLP
  • USA
  • January 17 2017

On November 8, 2016, voters in Massachusetts (along with their counterparts in Maine, California, and Nevada) voted to legalize the recreational use


Supreme Court Will Judge Biosimilar Patent Dance
  • Foley & Lardner LLP
  • USA
  • January 16 2017

The U.S. Supreme Court has agreed to review some of the patent dispute resolution provisions of the Biologics Price Competition and Innovation Act


OIG Rings in the New Year With New Anti-Kickback Statute Safe Harbors
  • Foley & Lardner LLP
  • USA
  • January 12 2017

Just in time for the New Year, the Office of Inspector General (OIG) of the U.S. Department of Health and Human Services issued final regulations


Florida Board of Medicine Hearing on Telemedicine and Medical Marijuana
  • Foley & Lardner LLP
  • USA
  • January 11 2017

The Florida Board of Medicine will hold a public hearing on February 3, 2017 to discuss its proposed amendment to Florida’s telemedicine practice


HRSA Announces Final Rule on Civil Monetary Penalties for Drug Manufacturers that Overcharge 340B Covered Entities
  • Foley & Lardner LLP
  • USA
  • January 10 2017

A new regulation issued by the Health Resources and Services Administration (“HRSA”) sets forth a process by which civil monetary penalties may be


The Joint Commission Bans Text Messaging for Patient Care Orders
  • Foley & Lardner LLP
  • USA
  • January 9 2017

The Joint Commission, which accredits hospitals and other health care organizations, recently announced it will not permit hospitals and other health


FDA Releases Biosimilar Guidance for Industry
  • Foley & Lardner LLP
  • USA
  • January 9 2017

On December 29, 2016, the FDA issued guidance to assist applicants seeking FDA approval of a proposed biosimilar product under the Biologics Price


Cures Act Lets Small Employers Reimburse Premiums
  • Foley & Lardner LLP
  • USA
  • January 4 2017

On December 13, 2016, President Obama signed into law the 21st Century Cures Act, which allows small employers to maintain health reimbursement